Journal of Pharmaceutical Policy and Practice (Dec 2024)

Availability and pricing of insulin and related diagnostics in South Africa

  • Samirah Bayat,
  • Velisha Ann Perumal-Pillay,
  • Fatima Suleman

DOI
https://doi.org/10.1080/20523211.2024.2372467
Journal volume & issue
Vol. 17, no. 1

Abstract

Read online

Background In South Africa (SA), most patients rely on the government for free healthcare. Some choose to subscribe to a medical insurance scheme. If insulin is unavailable in government or otherwise unaffordable, non-adherence may occur, which can increase complications of the disease.Methods Data on availability and pricing of insulin and related diagnostics was collected from SA pharmacies via an online survey. Co-payments levied on insulin by the biggest medical aids were extracted from formularies. Affordability of these items was then assessed. An adapted methodology from the World Health Organization/Health Action International tool was used.Results There was fairly high availability of insulin in the public sector, with the exception of long-acting insulin which respondents claimed was difficult to find; however, long-acting insulin glargine was available in most private sector pharmacies. Point-of-care (POC) blood glucose testing was free in the public sector but offered in only 31.25% of pharmacies. Patients pay a minimum of USD 40.4 (over 3 days’ wages for the lowest paid government worker (LPGW)) for a months’ supply of the cheapest insulin, needles and test strips. Insulin in SA was cheaper than 5 other countries, except Australia.Conclusion Overall, there is a good availability of insulin and related diagnostics in SA. Even though insulin is cheaper than other countries, it is unaffordable to the LPGW. This highlights the importance of ensuring a constant availability of insulin in the free public sector. Whilst human insulins are cheaper than newer analogue insulins and SA faces cost constraints, important variables in favour of newer insulins, such as ease-of-use, long term outcomes and value should be considered when treatment guidelines are updated. Annual POC testing should be available and offered free to all patients to detect diabetes early.

Keywords